NO20065107L - PGD2 reseptor antagonister for behandling av inflammatoriske sykdommer - Google Patents
PGD2 reseptor antagonister for behandling av inflammatoriske sykdommerInfo
- Publication number
- NO20065107L NO20065107L NO20065107A NO20065107A NO20065107L NO 20065107 L NO20065107 L NO 20065107L NO 20065107 A NO20065107 A NO 20065107A NO 20065107 A NO20065107 A NO 20065107A NO 20065107 L NO20065107 L NO 20065107L
- Authority
- NO
- Norway
- Prior art keywords
- treatment
- receptor antagonists
- inflammatory diseases
- pgd2 receptor
- structural formulas
- Prior art date
Links
- 108050000258 Prostaglandin D receptors Proteins 0.000 title abstract 2
- 208000027866 inflammatory disease Diseases 0.000 title abstract 2
- 102000009389 Prostaglandin D receptors Human genes 0.000 title 1
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 abstract 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 abstract 1
- 102100024218 Prostaglandin D2 receptor 2 Human genes 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
- C07D215/44—Nitrogen atoms attached in position 4 with aryl radicals attached to said nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Transplantation (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Quinoline Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US56041004P | 2004-04-07 | 2004-04-07 | |
| PCT/US2005/011643 WO2005100321A1 (en) | 2004-04-07 | 2005-04-07 | Pgd2 receptor antagonists for the treatment of inflammatory diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20065107L true NO20065107L (no) | 2006-12-01 |
Family
ID=34965223
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20065107A NO20065107L (no) | 2004-04-07 | 2006-11-06 | PGD2 reseptor antagonister for behandling av inflammatoriske sykdommer |
Country Status (21)
| Country | Link |
|---|---|
| EP (1) | EP1740547A1 (es) |
| JP (1) | JP2007532555A (es) |
| KR (1) | KR20070002085A (es) |
| CN (1) | CN101018770A (es) |
| AR (1) | AR048528A1 (es) |
| AU (1) | AU2005233125A1 (es) |
| BR (1) | BRPI0509668A (es) |
| CA (1) | CA2561564A1 (es) |
| CL (1) | CL2008000069A1 (es) |
| CR (1) | CR8659A (es) |
| EC (1) | ECSP066977A (es) |
| IL (1) | IL178328A0 (es) |
| MA (1) | MA28566B1 (es) |
| MX (1) | MXPA06011540A (es) |
| NO (1) | NO20065107L (es) |
| RU (1) | RU2006138603A (es) |
| TN (1) | TNSN06320A1 (es) |
| TW (1) | TW200538127A (es) |
| UA (1) | UA84749C2 (es) |
| WO (1) | WO2005100321A1 (es) |
| ZA (1) | ZA200608955B (es) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1861372A1 (en) | 2005-02-24 | 2007-12-05 | Millennium Pharmaceuticals, Inc. | Pgd2 receptor antagonists for the treatment of inflammatory diseases |
| EP1717235A3 (en) * | 2005-04-29 | 2007-02-28 | Bioprojet | Phenoxypropylpiperidines and -pyrrolidines and their use as histamine H3-receptor ligands |
| CA2616937A1 (en) | 2005-07-29 | 2007-02-08 | F. Hoffman-La Roche Ag | Indol-3-yl-carbonyl-piperidin and piperazin derivatives |
| PT2037967T (pt) | 2006-06-16 | 2017-03-14 | Univ Pennsylvania | Antagonistas do recetor de prostaglandina d2 para o tratamento da alopecia androgenética |
| JP2010501567A (ja) | 2006-08-24 | 2010-01-21 | ノバルティス アクチエンゲゼルシャフト | 代謝系、心血管系および他の障害の処置のためのステアロイル−ＣｏＡ不飽和化酵素（ＳＣＤ）阻害剤としての２−（ピラジン−２−イル）−チアゾールおよび２−（１Ｈ−ピラゾール−３−イル）チアゾール誘導体ならびに関連化合物 |
| WO2008029924A1 (en) | 2006-09-08 | 2008-03-13 | Dainippon Sumitomo Pharma Co., Ltd. | Cyclic aminoalkylcarboxamide derivative |
| JP5351025B2 (ja) | 2006-09-22 | 2013-11-27 | ノバルティス アーゲー | ヘテロ環式有機化合物 |
| KR20090091337A (ko) | 2006-12-20 | 2009-08-27 | 노파르티스 아게 | Ｓｃｄ 억제제로서의 ２-치환 ５-원 헤테로사이클 |
| WO2009041072A1 (ja) | 2007-09-27 | 2009-04-02 | Kowa Company, Ltd. | テトラヒドロキノリン化合物を有効成分とする貧血の予防及び／又は治療剤 |
| DK2229358T3 (da) | 2007-12-14 | 2011-07-04 | Pulmagen Therapeutics Asthma Ltd | Indoler og deres terapeutiske anvendelse |
| JP2011102241A (ja) * | 2008-03-04 | 2011-05-26 | Dainippon Sumitomo Pharma Co Ltd | 新規１−アミノカルボニルピペリジン誘導体 |
| JP5731385B2 (ja) | 2008-08-22 | 2015-06-10 | バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ | ポリマーベンジルカルボネート誘導体 |
| JP2011256110A (ja) * | 2008-09-30 | 2011-12-22 | Takeda Chem Ind Ltd | ヘキサヒドロピロロキノリンの製造法 |
| EP2415764A4 (en) | 2009-03-31 | 2012-08-08 | Kowa Co | PROPHYLACTIC AND / OR THERAPEUTIC AGENT AGAINST ANEMIA WITH A TETRAHYDROCHINOLINE COMPOUND AS AN ACTIVE SUBSTANCE |
| GB0919431D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| US9360482B2 (en) | 2009-11-05 | 2016-06-07 | Glaxosmithkline Llc | Process for the identification of a compound which inhibits the binding of the second bromodomain of each of human BRD-2, BRD-3, and BRD-4 |
| US8575158B2 (en) | 2010-07-05 | 2013-11-05 | Actelion Pharmaceuticals Ltd. | 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin D2 receptor modulators |
| EP2457900A1 (en) | 2010-11-25 | 2012-05-30 | Almirall, S.A. | New pyrazole derivatives having CRTh2 antagonistic behaviour |
| EA025100B1 (ru) | 2011-06-17 | 2016-11-30 | Мерк Шарп И Доум Корп. | Циклоалкил-конденсированные тетрагидрохинолины в качестве модуляторов рецепторов crth |
| SG11201402796SA (en) | 2011-12-16 | 2014-06-27 | Atopix Therapeutics Ltd | Combination of crth2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis |
| BR112014015081A8 (pt) | 2011-12-21 | 2017-06-13 | Actelion Pharmaceuticals Ltd | derivados heterocíclicos e seu uso como moduladores do receptor d2 de prostaglandina |
| JP6127135B2 (ja) | 2012-07-05 | 2017-05-10 | アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ | １−フェニル置換ヘテロシクリル誘導体及びプロスタグランジンｄ２受容体調節剤としてのそれらの使用 |
| WO2016128565A1 (en) | 2015-02-13 | 2016-08-18 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Ptgdr-1 and/or ptgdr-2 antagonists for preventing and/or treating systemic lupus erythematosus |
| HK1256553A1 (zh) | 2015-07-30 | 2019-09-27 | The Trustees Of The University Of Pennsylvania | 用於检测pgd2对毛发生长抑制的易感性的人dp-2基因的单核苷酸多态性等位基因 |
| JOP20190105A1 (ar) * | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
| KR102798145B1 (ko) | 2018-04-18 | 2025-04-22 | 콘스텔레이션 파마슈티칼스, 인크. | 메틸 변형 효소 조절제, 이의 조성물 및 용도 |
| CA3100977A1 (en) | 2018-05-21 | 2019-11-28 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| CN113201316B (zh) * | 2021-04-25 | 2022-08-26 | 西南石油大学 | 温度/CO2/pH多重响应性乳化剂和乳状液及其应用 |
| CN116425623B (zh) * | 2023-04-10 | 2024-02-13 | 大连凯飞化学股份有限公司 | 一锅法合成3,5-二氯-4-甲基苯甲酸的方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2326419A1 (en) * | 1998-03-31 | 1999-10-07 | Shionogi & Co., Ltd. | Process for producing 5-hydroxybenzo[b]thiophene-3-carboxylic acid derivatives |
| PL366700A1 (en) * | 2001-04-30 | 2005-02-07 | Pfizer Products Inc. | Methods for preparing cetp inhibitors |
| JP2003321471A (ja) * | 2002-04-30 | 2003-11-11 | Fuji Photo Film Co Ltd | ラクタム化合物及びその製造方法 |
| US20040053842A1 (en) * | 2002-07-02 | 2004-03-18 | Pfizer Inc. | Methods of treatment with CETP inhibitors and antihypertensive agents |
| EP1556047A4 (en) * | 2002-10-04 | 2009-09-30 | Millennium Pharm Inc | ANTAGONISTS AGAINST THE PGD2 RECEPTOR FOR THE TREATMENT OF INFLAMMATORY DISEASES |
| ATE327977T1 (de) * | 2002-10-21 | 2006-06-15 | Warner Lambert Co | Tetrahydrochinolin-derivate als crth2 antagonisten |
| JPWO2004052863A1 (ja) * | 2002-12-06 | 2006-04-13 | 協和醗酵工業株式会社 | 抗炎症剤 |
| EP1435356A1 (en) * | 2003-01-06 | 2004-07-07 | Warner-Lambert Company LLC | Quinoline derivatives as CRTH2 antagonists |
-
2005
- 2005-04-07 AU AU2005233125A patent/AU2005233125A1/en not_active Withdrawn
- 2005-04-07 JP JP2007507467A patent/JP2007532555A/ja active Pending
- 2005-04-07 TW TW094111008A patent/TW200538127A/zh unknown
- 2005-04-07 AR ARP050101369A patent/AR048528A1/es unknown
- 2005-04-07 CA CA002561564A patent/CA2561564A1/en not_active Abandoned
- 2005-04-07 BR BRPI0509668-5A patent/BRPI0509668A/pt not_active IP Right Cessation
- 2005-04-07 EP EP05733968A patent/EP1740547A1/en not_active Withdrawn
- 2005-04-07 RU RU2006138603/04A patent/RU2006138603A/ru not_active Application Discontinuation
- 2005-04-07 UA UAA200611678A patent/UA84749C2/ru unknown
- 2005-04-07 KR KR1020067023323A patent/KR20070002085A/ko not_active Ceased
- 2005-04-07 WO PCT/US2005/011643 patent/WO2005100321A1/en not_active Ceased
- 2005-04-07 CN CNA200580018590XA patent/CN101018770A/zh active Pending
- 2005-04-07 MX MXPA06011540A patent/MXPA06011540A/es not_active Application Discontinuation
-
2006
- 2006-09-27 IL IL178328A patent/IL178328A0/en unknown
- 2006-09-27 CR CR8659A patent/CR8659A/es not_active Application Discontinuation
- 2006-10-06 TN TNP2006000320A patent/TNSN06320A1/en unknown
- 2006-10-27 ZA ZA200608955A patent/ZA200608955B/xx unknown
- 2006-11-02 MA MA29430A patent/MA28566B1/fr unknown
- 2006-11-06 NO NO20065107A patent/NO20065107L/no not_active Application Discontinuation
- 2006-11-08 EC EC2006006977A patent/ECSP066977A/es unknown
-
2008
- 2008-01-10 CL CL200800069A patent/CL2008000069A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW200538127A (en) | 2005-12-01 |
| RU2006138603A (ru) | 2008-05-20 |
| ECSP066977A (es) | 2006-12-29 |
| MA28566B1 (fr) | 2007-05-02 |
| CA2561564A1 (en) | 2005-10-27 |
| CN101018770A (zh) | 2007-08-15 |
| BRPI0509668A (pt) | 2007-10-09 |
| EP1740547A1 (en) | 2007-01-10 |
| CR8659A (es) | 2007-06-08 |
| AU2005233125A1 (en) | 2005-10-27 |
| WO2005100321A1 (en) | 2005-10-27 |
| MXPA06011540A (es) | 2007-01-26 |
| IL178328A0 (en) | 2007-02-11 |
| JP2007532555A (ja) | 2007-11-15 |
| UA84749C2 (ru) | 2008-11-25 |
| ZA200608955B (en) | 2009-05-27 |
| CL2008000069A1 (es) | 2008-05-16 |
| KR20070002085A (ko) | 2007-01-04 |
| AR048528A1 (es) | 2006-05-03 |
| TNSN06320A1 (en) | 2008-02-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20065107L (no) | PGD2 reseptor antagonister for behandling av inflammatoriske sykdommer | |
| NO20051566L (no) | PGD2 reseptor antagonister for behandling av inflammatoriske sykdommer | |
| NO20070489L (no) | 3-aminocyklopentankarboksamider som modulatorer av kjemokinreseptorer. | |
| BRPI0408369A (pt) | derivados de indol úteis para o tratamento de doenças | |
| NO20070466L (no) | Pyrrolopyrimidin og pyrrolopyridinderivater substituert med en cyklisk aminogruppe som CRF antagonister | |
| NO20083411L (no) | Indaneddiksyrederivater og deres anvendelse som farmasoytiske midler, intermediater og fremgangsmater for fremstilling | |
| NO20070467L (no) | Pyrrolopyrimidin og pyrrolopyridinderivater substituert med tetrahydropyridin som CRF antagonister | |
| NO20063928L (no) | Substituerte kinolinforbindelser | |
| EA200200921A1 (ru) | Полуамиды малоновой кислоты и их производные в качестве лигандов тиреоидных рецепторов | |
| DE60005485D1 (de) | Indolderivate und ihre verwendung als mcp-1 rezeptor antagonisten | |
| NO20054769L (no) | Substituerte fenylalkansyrer | |
| WO2005018529A3 (en) | Phenoxiacetic acid derivatives | |
| MX2007003335A (es) | Acidos aceticos de bencimidazol que muestran antagonismo de receptor crth2 y usos de los mismos. | |
| EA201171197A8 (ru) | Замещенные производные азоантрацена, фармацевтические композиции и способы их применения | |
| NO20052595L (no) | Sammensetninger anvendelige som inhibitorer av ROCK- og andre proteinkinaser. | |
| NO20076059L (no) | 2,4-Diamino-pyrimidiner anvendt som aurorainhibitorer | |
| NO20065230L (no) | Kondenserte pyridinderivater anvendelige som A28 adenosinreseptorantagonister | |
| DE602004012858D1 (de) | 2-aminobenzothiazole als cb1 rezeptor inverse agonisten | |
| DK1716152T3 (da) | Kondenserade heterocykliske forbindelser og deres anvendelse som metabotrope receptorantagonister til behandling af gastrointentinde lidelser | |
| ATE384058T1 (de) | Thiazolderivate | |
| NO20063761L (no) | Sulfonamidderivater for behandling av sykdommer | |
| NO20053792L (no) | Heterocykly-3-sulfonylindazoler som 5-hydroksytryptamin-6 ligander | |
| WO2004058174A3 (en) | Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation | |
| NO20065678L (no) | 3-(4-heteroarylcykloheksylamino) cyklopentankarboksamider som modulatorer for kjemokinreseptorer. | |
| EA200601462A1 (ru) | Соединения для лечения заболеваний |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |